|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Collins K, Jacks T and Pavletich NP: The
cell cycle and cancer. Proc Natl Acad Sci USA. 94:2776–2778. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dominguez-Brauer C, Thu KL, Mason JM,
Blaser H, Bray MR and Mak TW: Targeting Mitosis in cancer: Emerging
strategies. Mol Cell. 60:524–536. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Otto T and Sicinski P: Cell cycle proteins
as promising targets in cancer therapy. Nat Rev Cancer. 17:93–115.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kastan MB and Bartek J: Cell-cycle
checkpoints and cancer. Nature. 432:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sanchez-Martinez C, Gelbert LM, Lallena MJ
and de Dios A: Cyclin dependent kinase (CDK) inhibitors as
anticancer drugs. Bioorg Med Chem Lett. 25:3420–3435. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shah A, Bloomquist E, Tang S, Fu W, Bi Y,
Liu Q, Yu J, Zhao P, Palmby TR, Goldberg KB, et al: FDA approval:
Ribociclib for the treatment of postmenopausal women with hormone
receptor-positive, HER2-negative advanced or metastatic breast
cancer. Clin Cancer Res. 24:2999–3004. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Asghar U, Witkiewicz AK, Turner NC and
Knudsen ES: The history and future of targeting cyclin-dependent
kinases in cancer therapy. Nat Rev Drug Discov. 14:130–146. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wedam S, Fashoyin-Aje L, Bloomquist E,
Tang S, Sridhara R, Goldberg KB, Theoret MR, Amiri-Kordestani L,
Pazdur R and Beaver JA: FDA approval summary: Palbociclib for male
patients with metastatic breast cancer. Clin Cancer Res.
26:1208–1212. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
FDA expands approved use of ibrance
(Palbociclib) for HR+, HER2-metastatic breast cancer. Oncol Times.
38:222016. View Article : Google Scholar
|
|
11
|
Martin JM and Goldstein LJ: Profile of
abemaciclib and its potential in the treatment of breast cancer.
Onco Targets Ther. 11:5253–5259. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jin D, Tran N, Thomas N and Tran DD:
Combining CDK4/6 inhibitors ribociclib and palbociclib with
cytotoxic agents does not enhance cytotoxicity. PLoS One.
14:e02235552019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu A, Wu B, Guo J, Luo W, Wu D, Yang H,
Zhen Y, Yu X, Wang H, Zhou Y, et al: Elevated expression of CDK4 in
lung cancer. J Transl Med. 9:382011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gong W, Wang L, Zheng Z, Chen W, Du P and
Zhao H: Cyclin-dependent kinase 6 (CDK6) is a candidate diagnostic
biomarker for early non-small cell lung cancer. Transl Cancer Res.
9:95–103. 2019. View Article : Google Scholar
|
|
15
|
Thangavel C, Boopathi E, Liu Y, McNair C,
Haber A, Perepelyuk M, Bhardwaj A, Addya S, Ertel A, Shoyele S, et
al: Therapeutic challenge with a CDK 4/6 Inhibitor Induces an
RB-Dependent SMAC-Mediated apoptotic response in non-small cell
lung cancer. Clin Cancer Res. 24:1402–1414. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Patnaik A, Rosen LS, Tolaney SM, Tolcher
AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW,
Hilton JF, et al: Efficacy and safety of abemaciclib, an inhibitor
of CDK4 and CDK6, for patients with breast cancer, non-small cell
lung cancer, and other solid tumors. Cancer Discov. 6:740–753.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pacheco J and Schenk E: CDK4/6 inhibition
alone and in combination for non-small cell lung cancer.
Oncotarget. 10:618–619. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Waddell N, Pajic M, Patch AM, Chang DK,
Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al:
Whole genomes redefine the mutational landscape of pancreatic
cancer. Nature. 518:495–501. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Witkiewicz AK, McMillan EA, Balaji U, Baek
G, Lin WC, Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, et
al: Whole-exome sequencing of pancreatic cancer defines genetic
diversity and therapeutic targets. Nat Commun. 6:67442015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Serrano M, Lin AW, McCurrach ME, Beach D
and Lowe SW: Oncogenic ras provokes premature cell senescence
associated with accumulation of p53 and p16INK4a. Cell. 88:593–602.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Weinberg F, Hamanaka R, Wheaton WW,
Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger
GR and Chandel NS: Mitochondrial metabolism and ROS generation are
essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA.
107:8788–8793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Garcia-Reyes B, Kretz AL, Ruff JP, von
Karstedt S, Hillenbrand A, Knippschild U, Henne-Bruns D and Lemke
J: The emerging role of cyclin-dependent kinases (CDKs) in
pancreatic ductal adenocarcinoma. Int J Mol Sci. 19:32192018.
View Article : Google Scholar
|
|
23
|
Knudsen ES, Kumarasamy V, Ruiz A, Sivinski
J, Chung S, Grant A, Vail P, Chauhan SS, Jie T, Riall TS and
Witkiewicz AK: Cell cycle plasticity driven by MTOR signaling:
Integral resistance to CDK4/6 inhibition in patient-derived models
of pancreatic cancer. Oncogene. 38:3355–3370. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Franco J, Balaji U, Freinkman E,
Witkiewicz AK and Knudsen ES: Metabolic reprogramming of pancreatic
cancer mediated by CDK4/6 inhibition elicits unique
vulnerabilities. Cell Rep. 14:979–990. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu F and Korc M: Cdk4/6 inhibition
induces epithelial-mesenchymal transition and enhances invasiveness
in pancreatic cancer cells. Mol Cancer Ther. 11:2138–2148. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Franco J, Witkiewicz AK and Knudsen ES:
CDK4/6 inhibitors have potent activity in combination with pathway
selective therapeutic agents in models of pancreatic cancer.
Oncotarget. 5:6512–6525. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Santamaria D, Barriere C, Cerqueira A,
Hunt S, Tardy C, Newton K, Cáceres JF, Dubus P, Malumbres M and
Barbacid M: Cdk1 is sufficient to drive the mammalian cell cycle.
Nature. 448:811–815. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Malumbres M, Sotillo R, Santamaria D,
Galán J, Cerezo A, Ortega S, Dubus P and Barbacid M: Mammalian
cells cycle without the D-type cyclin-dependent kinases Cdk4 and
Cdk6. Cell. 118:493–504. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Piao J, Zhu L, Sun J, Li N, Dong B, Yang Y
and Chen L: High expression of CDK1 and BUB1 predicts poor
prognosis of pancreatic ductal adenocarcinoma. Gene. 701:15–22.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dong S, Huang F, Zhang H and Chen Q:
Overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues
predicts poor survival in pancreatic ductal adenocarcinoma. Biosci
Rep. 39:BSR201823062019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shi YX, Zhu T, Zou T, Zhuo W, Chen YX,
Huang MS, Zheng W, Wang CJ, Li X, Mao XY, et al: Prognostic and
predictive values of CDK1 and MAD2L1 in lung adenocarcinoma.
Oncotarget. 7:85235–85243. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li M, He F, Zhang Z, Xiang Z and Hu D:
CDK1 serves as a potential prognostic biomarker and target for lung
cancer. J Int Med Res. 48:3000605198975082020.PubMed/NCBI
|
|
33
|
O'Brien J, Hayder H, Zayed Y and Peng C:
Overview of MicroRNA biogenesis, mechanisms of actions, and
circulation. Front Endocrinol (Lausanne). 9:4022018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hossian AK, Muthumula CM, Sajib MS, Tullar
PE, Stelly AM, Briski KP, Mikelis CM and Matthaiolampakis G:
Analysis of combinatorial miRNA treatments to regulate cell cycle
and angiogenesis. J Vis Ex. e594602019.
|
|
35
|
Hossian AKMN, Sajib MS, Tullar PE, Mikelis
CM and Mattheolabakis G: Multipronged activity of combinatorial
miR-143 and miR-506 inhibits lung cancer cell cycle progression and
angiogenesis in vitro. Sci Rep. 8:104952018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
StarBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42:D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang JH, Li JH, Shao P, Zhou H, Chen YQ
and Qu LH: StarBase: A database for exploring microRNA-mRNA
interaction maps from Argonaute CLIP-Seq and degradome-Seq data.
Nucleic Acids Res. 39:D202–D209. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Thul PJ and Lindskog C: The human protein
atlas: A spatial map of the human proteome. Protein Sci.
27:233–244. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Uhlen M, Fagerberg L, Hallstrom BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang N, Su Y and Xu L: Targeting PKCε by
miR-143 regulates cell apoptosis in lung cancer. FEBS Lett.
587:3661–3667. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
van Caloen G, Schmitz S, El Baroudi M,
Caignet X, Pyr Dit Ruys S, Roger PP, Vertommen D and Machiels JP:
Preclinical activity of ribociclib in squamous cell carcinoma of
the head and neck. Mol Cancer Ther. 19:777–789. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wong CH, Ma BB, Hui CW, Lo KW, Hui EP and
Chan AT: Preclinical evaluation of ribociclib and its synergistic
effect in combination with alpelisib in non-keratinizing
nasopharyngeal carcinoma. Sci Rep. 8:80102018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kelland LR: Flavopiridol, the first
cyclin-dependent kinase inhibitor to enter the clinic: Current
status. Expert Opin Investig Drugs. 9:2903–2911. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Saisomboon S, Kariya R, Vaeteewoottacharn
K, Wongkham S, Sawanyawisuth K and Okada S: Antitumor effects of
flavopiridol, a cyclin-dependent kinase inhibitor, on human
cholangiocarcinoma in vitro and in an in vivo xenograft model.
Heliyon. 5:e016752019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Senderowicz AM and Sausville EA:
Preclinical and clinical development of cyclin-dependent kinase
modulators. J Natl Cancer Inst. 92:376–387. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hossian AKMN, Mackenzie GG and
Mattheolabakis G: miRNAs in gastrointestinal diseases: Can we
effectively deliver RNA-based therapeutics orally? Nanomedicine
(Lond). 14:2873–2889. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Labatut AE and Mattheolabakis G: Non-viral
based miR delivery and recent developments. Eur J Pharm Biopharm.
128:82–90. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhao W, Zhao SP and Zhao YH:
MicroRNA-143/-145 in cardiovascular diseases. Biomed Res Int.
2015:5317402015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lovendorf MB, Zibert JR, Gyldenlove M,
Ropke MA and Skov L: MicroRNA-223 and miR-143 are important
systemic biomarkers for disease activity in psoriasis. J Dermatol
Sci. 75:133–139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Anton L, DeVine A, Sierra LJ, Brown AG and
Elovitz MA: miR-143 and miR-145 disrupt the cervical epithelial
barrier through dysregulation of cell adhesion, apoptosis and
proliferation. Sci Rep. 7:30202017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Liu G, Sun Y, Ji P, Li X, Cogdell D, Yang
D, Parker Kerrigan BC, Shmulevich I, Chen K, Sood AK, et al:
MiR-506 suppresses proliferation and induces senescence by directly
targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol.
233:308–318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yin M, Ren X, Zhang X, Luo Y, Wang G,
Huang K, Feng S, Bao X, Huang K, He X, et al: Selective killing of
lung cancer cells by miRNA-506 molecule through inhibiting NF-κB
p65 to evoke reactive oxygen species generation and p53 activation.
Oncogene. 34:691–703. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Li J, Wu H, Li W, Yin L, Guo S, Xu X,
Ouyang Y, Zhao Z, Liu S, Tian Y, et al: Downregulated miR-506
expression facilitates pancreatic cancer progression and
chemoresistance via SPHK1/Akt/NF-κB signaling. Oncogene.
35:5501–5514. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Senderowicz AM: Flavopiridol: The first
cyclin-dependent kinase inhibitor in human clinical trials. Invest
New Drugs. 17:313–320. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Deep A, Marwaha RK, Marwaha MG, Jyoti,
Nandal R and Sharma AK: Flavopiridol as cyclin dependent kinase
(CDK) inhibitor: A review. New J Chem. 42:18500–18507. 2018.
View Article : Google Scholar
|
|
57
|
Sunaga N, Shames DS, Girard L, Peyton M,
Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, et al:
Knockdown of oncogenic KRAS in non-small cell lung cancers
suppresses tumor growth and sensitizes tumor cells to targeted
therapy. Mol Cancer Ther. 10:336–346. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Berger AH, Brooks AN, Wu X, Shrestha Y,
Chouinard C, Piccioni F, Bagul M, Kamburov A, Imielinski M,
Hogstrom L, et al: High-throughput phenotyping of lung cancer
somatic mutations. Cancer Cell. 30:214–228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hung MS, Chen IC, Lin PY, Lung JH, Li YC,
Lin YC, Yang CT and Tsai YH: Epidermal growth factor receptor
mutation enhances expression of vascular endothelial growth factor
in lung cancer. Oncol Lett. 12:4598–4604. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Korc M: Driver mutations: A roadmap for
getting close and personal in pancreatic cancer. Cancer Biol Ther.
10:588–591. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Timar J and Kashofer K: Molecular
epidemiology and diagnostics of KRAS mutations in human cancer.
Cancer Metastasis Rev. 39:1029–1038. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Gradiz R, Silva HC, Carvalho L, Botelho MF
and Mota-Pinto A: MIA PaCa-2 and PANC-1-pancreas ductal
adenocarcinoma cell lines with neuroendocrine differentiation and
somatostatin receptors. Sci Rep. 6:216482016. View Article : Google Scholar : PubMed/NCBI
|
